$TEM

Doudna Jennifer A sold $147K of TEM

Doudna Jennifer A sold 2,673 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.15M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doudna Jennifer A
Published Jun 30, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosure updates the record of insider activity: a director open-market sale of 2,673 shares at $55.00/share, totaling $147,015, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 structure and lack of new fundamentals make this a low-impact datapoint.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no buy activity, and no linkage to performance or guidance—limiting interpretability.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed late June 29 (covers sale dated June 25).

Background

This is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by director Jennifer A Doudna.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director Jennifer A Doudna sold 2,673 shares in an open-market transaction for about $147K under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.

Evidence & confidence

The filing is a director open-market sale explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational, financial, or regulatory change disclosed.

Market effects

Minimal; insider-sale Form 4s typically do not reset sector expectations without additional company-specific news.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish views—so any negative read-through may be overdone.

Key entities

  • Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; director sale disclosed.

  • Jennifer A Doudna

    Director who sold 2,673 shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.